ANALYSIS OF THE CLINICAL EFFICACY AND SAFETY OF RT-PA IN TREATMENT OF ACUTE IS- CHEMIC STROKE

Junyi Wu*, Xiaoyun Zeng, ZhiXiu Luo, Jie Zhou*

Department of Neurology, Wuhan Pu Ai hospital, Wuhan, Hubei, China

Objective: To investigate the clinical effect of serum CEA, CA153, CYFRA21-1, CA125, NSE, and CA199 in the application of Myrian imaging rObjective: To investigate the efficacy and safety of recombinant tissue plasminogen activator (rt-PA) in treatment of acute ischemic stroke (AIS).

Methods: We selected a total of 60 of AIS patients who were admitted to this hospital in 2007 for rt-PA treatment, so as to eval- uate the clinical efficacy and safety.

Results: Six hours following the thrombolysis, AIS patients experienced an decrease in NIHSS scores from the original (21.32±2.64) points to (15.87±3.25) points, which continued to decrease to (11.14±3.12) points at 24 h and (6.45±4.35) points at 7 d after thrombolysis (all P < 0.05). Comparisons of the NIHSS scores before thrombolysis, at 6 h, 24 h and 7 d after thrombolysis showed that the differences had statistical significance (P < 0.05). Following thrombolysis, levels of the total cholesterol (TC) and low-density lipoprotein cholesterin (LDL-C) were (3.66±1.78) mmol/L and (3.18±1.46) mmol/L, respectively, significantly lower than (5.68±1.31) mmol/L and (3.47±0.79) mmol/L before thrombolysis (P < 0.050. At 4.5 h after onset, 96.7% of patients (29/30) gained a fundamental recovery of nerve functions, with the restoration of daily performance.

Conclusion: At the treatment window within 4.5 h, rt-PA is safe and effective in treatment of AIS, which is worthy of being pro- moted in clinical practice.